Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET
Company Participants
Melanie Herman – Senior Director of Financial Planning and Analysis
Todd Davis – Chief Executive Officer
Karen Reeves – Senior Vice President of Investments and Head of Clinical Strategy
Tavo Espinoza – Chief Financial Officer
Conference Call Participants
Matt Hewitt – Craig-Hallum
Douglas Miehm – RBC Capital Markets
Joseph Pantginis – Wainwright
Trevor Allred – Oppenheimer
John Vandermosten – Zach Small Capital Research
Operator
Good morning. My name is Aaron, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Ligand’s Third Quarter 2024 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. Thank you.
With that, I would like to turn our call over to Melanie Herman, Senior Director of Financial Planning and Analysis. Melanie, you may begin.
Melanie Herman
Good morning, everyone, and welcome to Ligand’s third quarter earnings call. During the call today, we will review the financial results we released before today’s market open and offer commentary on our partner pipeline and business development activity, followed by a question and answer session. Our earnings release and a link to today’s webcast can be found in the Investor Relations section of our website at ligand.com.
With me on the call today are CEO, Todd Davis; Senior Vice President of Investments and Head of Clinical Strategy, Dr. Karen Reeves; and Chief Financial Officer, Tavo Espinoza.
This call is being recorded and the audio portion will be archived in the Investors section of our website.
On today’s call, we will make forward-looking statements regarding our financial results and other matters related to the company’s business. Please refer to the
Read the full article here
